Key Quantitative Figures
Financial impact not quantified in the disclosure. The company expects "meaningful revenue contribution" from this agreement.
Dates of Action
The supply agreement was entered into on 12th November, 2026. The intimation letter was dated and digitally signed on 13th November, 2026.
Parties Involved
- Novelix Pharmaceuticals Limited (Indian company)
- M/s axabio® NV, Belgium (Belgian biotechnology company)
Purpose and Rationale
The agreement establishes axabio NV as the supplier of natural astaxanthin derived from microalgae (Haematococcus pluvialis) to Novelix Pharmaceuticals. The rationale is to support the company's business operations and strengthen its product portfolio in the field of astaxanthin-based products.
Significant Terms and Conditions
Under the Supply Agreement dated 12th November, 2026, the company shall procure natural astaxanthin derived from microalgae (Haematococcus pluvialis) from axabio NV in accordance with:
- Mutually agreed specifications
- Quality requirements
- Commercial terms mutually agreed between the parties
Transaction Type
International supply agreement that does not fall within the purview of related party transactions. Confirmed to be executed at arm's length.
Scope of Business Operation
The agreement covers the supply of natural astaxanthin derived from microalgae (Haematococcus pluvialis) by axabio NV to Novelix Pharmaceuticals.
Expected Benefits
- Meaningful revenue contribution
- Support for business operations
- Strengthening of product portfolio in astaxanthin-based products